Navarro-Navarro M, Robles-Zepeda RE, Garibay-Escobar A, Ruiz-Bustos E

Language: Spanish
References: 13
Page: 341-344
PDF size: 182.31 Kb.

ABSTRACT

Objective. To determine the prevalence of extendedspectrum β-lactamases (ESBL)-producing Esherichia coli and Klebsiella pneumoniae in hospitals of Hermosillo, Sonora, Mexico. Material and Methods. To detect ESBL-production, 1 412 bacterial isolates obtained over a one year period (2008-2009) were analyzed using the double-disk synergy test, with and without clavulanic acid. Results. Hospitalaryacquired ESBL-producing E. coli and K. pneumoniae (31.8% and 35.3%) were isolated with higher prevalence that communityacquired isolates (14.4% and 0.0%) (p‹0.005). Conclusions. Our study shows the presence of ESBL-producing bacteria in the three hospitals.

REFERENCES

1. Katz OT, Peled N, Yagupsky P. Evaluation of the current National Committee for Clinical Laboratory Standards guidelines for screening and confirming extended-spectrum beta-lactamase production in isolates of Escherichia coli and Klebsiella species from bacteremic patients. Eur J Clin Microbiol Infect Dis 2004;23:813-817.

2. Hernández JR, Pascual A, Cantón R, Martínez-Martínez L. Grupo de estudio de infección hospitalaria (GEIH). Escherichia coli y Klebsiella pneumoniae productores de ß-lactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003;21:77-82.

3. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-166.

4. Falagas ME, Karageorgopoulos DE. Extended-spectrum b-lactamaseproducing organisms. J Hosp Inf 2009;73:345-354.

5. Silva J, Gatica R, Aguilar C, Becerra Z, Garza-Ramos U, Velázquez M, et al. Outbreak of infection with extended-spectrum β-lactamaseproducing Klebsiella pneumoniae in a mexican hospital. J Clin Microbiol 2001;39:3193-3196.

6. Garza-Ramos U, Martínez-Romero E, Silva-Sánchez J. SHV-type extended-spectrum β-lactamase (ESBL) are encoded in related plasmids from enterobacteria clinical isolates from Mexico. Salud Publica Mex 2007;49:415-421.

7. CLSI. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. Clinical and Laboratory Standards Institute 2008. M100-S18. Wayne, PA.

8. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific Region. Clin Inf Dis 2001;32(Suppl 2):S94-103.

9. Navarro-Navarro M, Moreno-Noriega BO, López-Munguía BE, Fragoso- Carmelo MC, Sánchez-Padilla JA. Detección de cepas de Escherichia coli y Klebsiella pneumoniae productoras de β-lactamasas de espectro extendido (BLEE) en el Hospital Infantil del Estado de Sonora. Bol Clin Hosp Inf Edo Son 2005;22:64-70.

10. Silva-Sanchez J, Garza-Ramos JU, Reyna-Flores F, Sanchez-Perez A, Rojas-Moreno T, Andrade-Almaraz V, et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae causing nosocomial infections in Mexico. A retrospective and multicenter study. Arch Med Res 2011;42:156-162.

11. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBLproducing enterobacteriaceae in Europe. Eurosurveillance 2008;13:1-11.

12. Mulvey MR, Bryce E, Boyd D, Ofner-Agostini M, Christianson S, Simor AE, et al. Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrobial Agents Chemother 2004;48:1204-1214.

13. Gniadkowsky M. Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001;7:597-608.